DIRECTORY
BIOTECH
Pharmaclient

   

Quick Click ! Monthly news Home-Site Menu-Site Contactexpress Faqs Legends Companies Events Environment Memories Home-Biotech

Abcys | AB Science | Adocia | Advicenne Pharma | Affichem | Agate Bioservices | Aisa Therapeutics | Alfact Innovation | Alizé Pharma | Ambiotis | Anaconda Pharma | Aptys Pharmaceuticals | Ariana Pharmaceuticals | Aterovax | Atlantic Bone Screen | Aureus Sciences | B Cell Design | BioAlliance Pharma | Biocortech | BioCydex | Biométhodes | Biom'up | BioProtein Technologies | BioQuanta | BioSystems International | BMSystems (Bio-Modeling) | Carmat | Cellectis | Cellial Technologies | CellProthera | CellVax | Cerenis Therapeutics | CliniGenetics | Covalab | Cytheris | Cytoo | DBV Technologies | Diaxonhit | DNA Therapeutics | Domain Therapeutics | Dynabio | Edelris | Endotis Pharma | Epixis | ERYtech Pharma | Eye Tech Care | Flamel Technologies | Fluofarma | GemacBio | Genepep | Genewave | Genfit | Genomic Vision | GenoSafe | GenoScience Pharma | Genoscreen | GenOway | Genticel | GTP Technology | Helios Biosciences | Hemarina | Hybrigenics | Hyphen BioMed | Imagene | ImmunId | Immutep | Imstar | In-Cell-Art | Indicia Biotechnology | InGen Biosciences | Innate Pharma | InnaVirVax | Innovative Health Diagnostics | IntegraGen | Ipsogen | I-Stem | Karcinolys | Keosys | MABlife | Magnisense | Mapreg | Mauna Kea Technologies | Medesis Pharma | Mellitech | Metabolys | MilleGen | Murigenetics | NanoBiotix | Neorphys | Neovacs | Netris-Pharma | Neuronax | NewVectys | NicOx | Nokad | Nosopharm | NovAliX | NovoCIB | Novotec | Obe Therapy | Oligovax | Oncodesign | OriBase Pharma | Oroxcell | Oxincell | Palumed | PharmaLeads | Pharnext | PhenoPro | Pherecydes Pharma | PolyIntell | Proteogenix | Protexel | PX'Therapeutics | Quantum Genomics | Rhenovia Pharma | ScarCell Therapeutics | Sisène Biotechnologies | Skuld-Tech | Stentys | Synapcell | Synprosis | Tc Land Expression | Theraclion | Theradiag | Theralpha | TheraVectys | Transgene | Trophos | TxCell | UROsphere | Vaxon Biotech | Vectalys | Vivalis | XenTech |

* IMMUTEP *


 

2001 - IDF
Orsay
(near Paris)
www.immutep.com

 

Discovery, Immunology
(also, Discovery, Diagnostics)
Key words: Cancer, Chronic Infectious Diseases, T Cell Immune responses, Immuno-therapy, MABs, Vaccines, Lag-3 protein
Mission: to develop immunostimulatory factors for the treatment of cancer and chronic infectious diseases and immunomodulatory therapeutic antibodies for the treatment of cancers or autoimmune diseases
Clients: Prescribers
admin@immutep.com

Age: 15 year(s)

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Spin-off |
Managing Dir.-CEO: Hawken (John B.) [co-founder, born 1948, Ms. chemistry (Oxford), MBA, ex-Diatos, EntoMed, Neurotech, Aptanomics, Shell]
Sc.Dir.-CSO: Triebel (Frédéric) [co-founder, born 1954, M.D., Ph.D. immunology, ex-Inserm, Prof. Immunology, Paris University, Institut Gustave Roussy (IGR)]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): Innoven Partenaires, H2I

Turnover (M€) : 0.02 (2009), 0.009 (2008), 0.009 (2006)
Total funding (M€) : 6.7
Last funding (M€) : 2.5
Focus : Cancers
Position : Clinical
Company confirm : none

 

History
DATEMILESTONETYPETIME
2011 .01 Licensing-out to GlaxoSmithKline for IMP731, a novel therapeutic antibody for the treatment of autoimmune diseases (upfront payment and milestones of up to 75 M€) LICOUT [9 years]
2009 .01 Clinical trial (phase II interim) for ImmuFact IMP321 associated with paclitaxel doubles clinical response rate in Metastatic Breast Cancer (confirmed in January 2010, with final results) CLIN [7 years]
2008 .10 Registration : FDA IND allowance for IMP321 in Pancreatic Cancer MKTG [7 years]
2005 .04 Clinical trial (phase II) for IMP321 (beginning) CLIN [3 years]
2005 .01 2nd round-financing : 2.5 M€, by Innoven, for the lead compound IMP321 (immuno-stimulation factor) RFINB [3 years]
2003 .12 1st round-financing : 2.5 M€, by FCPI La Poste Innovation, Innoven RFINA [2 years]
2001 .09 Company founded by Prof. Frédéric Triebel and John B. Hawken, as a spin-off from Institut Gustave Roussy (the largest cancer center clinic in Europe, located South of Paris) and Serono (today Merck-Serono) ORGF [0 year]

Actualisation / Updating: 6-May-2011

   


Pharmaclient est le site-conseil de la Valorisation Client en Pharma...
Pour toute Mission, Inscription à la Pharmagalerie, Insertion dans la base Biotech, ou Question: CONTACT



© J.H. Huber, Pharmaclient 2001-2017. Pour retourner à la page d'accueil Biotech: BIENVENUE !       Haut de page : légende